Recent large-scale genome-wide association studies (GWAS) in diverse populations have identified hundreds of genetic loci associated with T2D [7–9]. Polygenic risk scores (PRS), which aggregate the genetic risk of individual alleles across the genome, are thus promising to predict future T2D occurrence and improve early diagnosis, intervention, and prevention of T2D [10–15]. However, to date, T2D PRS were most widely developed and validated in individuals of European descent. Given that the predictive performance of PRS often attenuates in non-European populations [16], and communities of color are experiencing continuing increased rates of T2D [2–5], it is critically important to assess and optimize the transferability of T2D PRS in diverse populations before they can be deployed in clinical settings.
